ENSC
Ensysce Biosciences, Inc.1.1800
-0.0700-5.6%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
4.29MP/E (TTM)
-Basic EPS (TTM)
-6.35Dividend Yield
0%Recent Filings
8-K
Director resigns over retention pay
Ensysce Biosciences director Lee Rauch resigned effective March 24, 2026, citing disagreements with board actions, including her vote against $205,475 in severance packages for three managers and an extended 9-month retention deal for CFO Humphrey. These retention measures, approved March 27 amid strategic alternative reviews, aim to preserve enterprise value. Rauch chaired the Nominating Committee.
8-K
Corrects Series B scrivener's error
Ensysce Biosciences filed a Certificate of Correction on March 18, 2026, with Delaware to fix a scrivener's error in its Series B Preferred Stock designation, part of the Certificate of Incorporation. It corrects a clerical mistake without altering terms. No business impact disclosed. Filing occurred March 23.
8-K
Nasdaq bid price deficiency
Ensysce Biosciences received a Nasdaq deficiency notice on February 25, 2026, for failing the $1.00 minimum bid price over 30 consecutive business days, violating Listing Rule 5550(a)(2). It has 180 days until August 24, 2026, to sustain $1 closes for 10 straight business days. Stock trades uninterrupted under ENSC. Delisting risks capital access.
8-K
Annual meeting approvals passed
Ensysce Biosciences stockholders approved full issuance of shares and warrants to an investor (541,882 for, 195,475 against) and boosted the 2021 Omnibus Incentive Plan share pool from 121,457 to 721,457 (439,446 for) at the January 7, 2026 annual meeting. They elected William Chang and Lee Rauch as Class I directors and ratified Baker Tilly US as auditors for 2025. Nasdaq compliance secured.
8-K
Ensysce closes $4M financing
Ensysce Biosciences closed a $4M registered direct offering and private placement on November 14, 2025, issuing Series B Preferred Stock convertible at $2.50/share and warrants for 880,000 common shares at $2.50 exercise price. Net proceeds of ~$3.6M fund TAAP and MPAR program development plus working capital. Caps dilution at 19.99% pre-stockholder approval. Warrants exercisable after 6 months.
ADIL
Adial Pharmaceuticals, Inc
0.26-0.01
ENLV
Enlivex Therapeutics Ltd.
0.85-0.01
ENTA
Enanta Pharmaceuticals, Inc.
14.85-0.02
ENVB
Enveric Biosciences, Inc.
5.24-0.12
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
NTRB
Nutriband Inc.
4.49-0.35
PBM
Psyence Biomedical Ltd.
1.53+0.05
RAPP
Rapport Therapeutics, Inc.
30.76+1.16
TRDA
Entrada Therapeutics, Inc.
11.37+0.34